Valuation: Evofem Biosciences, Inc.

Market Cap 1.29M 1.13M 1.04M 962K 1.82M 123M 1.86M 12.51M 4.86M 60.24M 4.83M 4.72M 209M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.7M 48.86M 45.11M 41.68M 79M 5.33B 80.58M 542M 211M 2.61B 209M 205M 9.06B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-2.58%
1 week+7.95%
Current month+18.75%
1 month+15.85%
3 months+7.95%
6 months+3.26%
1 week 0.01
Extreme 0.008
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.82
5 years 0
Extreme 0.0008
1,950
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/01/24Sell

Chief Financial Officer

104 0.0010%
21/12/23Sell

Director

10 0.0001%
13/04/23Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-2.58%+7.95%+1.06%-98.73% 1.29M
-0.79%+2.87%+57.65%+170.54% 1,102B
-0.56%+4.58%+70.49%+66.52% 643B
-0.36%+1.19%+33.87%+88.90% 450B
-1.35%+1.86%+29.96%+26.26% 336B
-0.71%+0.72%+28.85%+46.77% 288B
-1.31%-0.26%-28.18%-39.13% 222B
+0.08%+2.11%+24.23%+64.18% 199B
-0.61%+7.57%+22.01%+79.02% 169B
+0.31%+1.28%-5.60%-32.22% 137B
Average -0.78%+4.20%+23.43%+37.21% 354.51B
Weighted average by Cap. -0.67%+2.07%+40.62%+86.32%

Financials

2024 2025
Net sales 19.36M 16.98M 15.68M 14.49M 27.46M 1.85B 28.01M 188M 73.24M 907M 72.71M 71.12M 3.15B 20.18M 17.7M 16.34M 15.1M 28.63M 1.93B 29.2M 196M 76.34M 946M 75.79M 74.13M 3.28B
Net income -8.86M -7.77M -7.17M -6.63M -12.57M -848M -12.82M -86.25M -33.51M -415M -33.27M -32.54M -1.44B 391K 343K 317K 293K 555K 37.44M 566K 3.81M 1.48M 18.32M 1.47M 1.44M 63.6M
Net Debt 45.84M 40.21M 37.12M 34.3M 65.02M 4.39B 66.32M 446M 173M 2.15B 172M 168M 7.46B 54.42M 47.73M 44.06M 40.72M 77.18M 5.21B 78.73M 530M 206M 2.55B 204M 200M 8.85B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
08/07/26 $0.009450 -2.58% 76,665
07/07/26 $0.009700 +7.78% 220,615
06/07/26 $0.009000 +12.50% 131,972
02/07/26 $0.008000 -9.09% 614,709
01/07/26 $0.008800 +10.41% 2,247,181

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock